A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
← catalyst calendarNCT05636176 · readout in 317 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
4,899actual
Sites
1,013
Countries
Argentina, Australia, Austria +43
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-08 | actual | When the study began enrolling |
| Primary completion | 2027-07-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-02 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Interventions
- Drug: Ziltivekimab
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF Visit
measured From randomisation (month 0) to end of study (up to 48 months)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed